Atrial fibrillation: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• GLP-1 5
• SGLT2 5
• NLRP3 0
• BTK 3
• AMPK 0
• PI3K 0
• GIP 3
• PPAR 0
• TTR 0
• AKT 0
• PCSK9 0
• STAT3 0
• BDNF 1
• COX-2 0
• ERK 0
• HMGB1 0
• HSP90 0
• IL-6 0
• METTL3 0
• NRF2 0
• PD-1 0
• PD-L1 0
• TP53 0
• VEGF 0
• ABL1 0
• ALK 0
• ANGPTL3 0
• APOE 0
• CD40 0
• CDK4/6 0
• CFTR 0
• EGFR 0
• FTO 0
• HER3 0
• HIF-1 0
• IGF1R 0
• RUNX1 0
• SIRT1 0
• STING 0
• STK11 0
• TLR4 0
• TNF 0
• TREM2 0
• YAP 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NICHD · R00

  Emotional and biobehavioral mechanisms of parent-infant emotional synchrony

  Children's Hosp of Philadelphia· Philadelphia, United States· US$248,999 awarded in fiscal year 2026· until Aug 2029

• NIH NINR · F31

  Clarifying symptom experiences and management strategies for breast cancer survivors with cardiotoxicity: A mixed-methods analysis

  University of South Florida· Tampa, United States· US$40,326 awarded in fiscal year 2026· until Jul 2028

• NIH NINR · R01

  SCH: Integrated AI and Sensing Systems for Mitigating Heart Failure Readmissions in High-Risk Groups with Obesity

  University of Pittsburgh at Pittsburgh· Pittsburgh, United States· US$1,200,000 awarded in fiscal year 2026· until Aug 2030

• NIH NIA · R43

  A Smart Remote Monitoring System for Cardiometabolic Management in Patients with Alzheimer's and Related Dementia

  Aventusoft, Llc· Boca Raton, United States· US$500,000 awarded in fiscal year 2026· until Sept 2027

• NIH NINDS · R56

  Characterizing a Calcium Channel Causing FASP: Examining Entrainment Changes as a Mechanism for Phase Advance

  University of California, San Francisco· San Francisco, United States· US$574,000 awarded in fiscal year 2026· until Aug 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Integrative Modeling of Autonomic dysfunction and Cardiac arrhyThmogenesis (IMpACT)

  Politecnico di Milano· Milano, Italy· EU contribution €193,643· until Aug 2029· 3 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Molecular, cellular, and pharmacological characterization of a new modality of familial arrhythmia (Na-CPVT)

  Linkopings Universitet· Linkoping, Sweden· EU contribution €252,180· until Jan 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Holistic Efficient Arrhythmic Risk Twinning for Post-MI Stratification (HEART-TWIN)

  Universidad Pompeu Fabra· Barcelona, Spain· EU contribution €209,915· until Dec 2028

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A computational framework for personalising atrial fibrillation treatment to minimise heart failure risk (AFHF-TAILOR)

  Eidgenoessische Technische Hochschule Zuerich· Zuerich, Switzerland· EU contribution €292,119· until Dec 2028· 2 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  Advanced Tissue Engineering, Bioprinting, and 5D Optogenetics for Arrhythmia Investigation and Treatment (OptoPrintRhythm)

  Technion - Israel Institute of Technology· Haifa, Israel· EU contribution €3,375,000· until Dec 2031

10 of 783 running projects, newest first. Listed amounts together: US$464.1m + €148.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 5
• Organoids 1
• Mendelian Randomization Analysis 75
• Gene Expression Profiling 31
• Whole Genome Sequencing 1
• Exome Sequencing 3
• Proteomics 16
• Metabolomics 14
• Mass Spectrometry 3
• Flow Cytometry 2
• Immunohistochemistry 2
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 67
• Machine Learning 88
• Deep Learning 35
• Cohort Studies 222
• Genome-Wide Association Study 62

• Benchmarking metabolic surrogate indices against body mass index for left atrial diameter in atrial fibrillation: a two-cohort study.

  Front Endocrinol (Lausanne), Nov 2026

• Risk of cardiovascular events and mortality associated with LDL and non-HDL cholesterol levels after statin initiation for primary prevention: A multiregional cohort study.

  PLoS Med, Nov 2026

• Ischaemic stroke and intracerebral haemorrhage in the post-acute phase after myocardial infarction: a nationwide cohort study in Sweden.

  Eur Stroke J, Nov 2026

• Metabolic Dysfunction-Associated Steatotic Liver Disease, With and Without Increased Alcohol Intake, and Incident Atrial Fibrillation in Older Korean Adults: A Competing-Risk Cohort Study.

  Geriatr Gerontol Int, Nov 2026

• Anticoagulation in Atrial Fibrillation With Previous Intracranial Bleeding: Competing Adverse Events in a Nationwide Cohort.

  Neurology, Oct 2026

• Early Rhythm Control vs Usual Care After Acute Ischemic Stroke in Patients With Atrial Fibrillation.

  Neurology, Oct 2026

• Same-Day Discharge Versus Overnight Stay After Catheter Ablation: An Observational Matched-Cohort Study on Safety and Feasibility.

  Dtsch Arztebl Int, Oct 2026

• Latent class analysis identifies three biologically distinct phenotypes among patients undergoing endovascular thrombectomy: a derivation and temporal validation study.

  Front Neurol, Oct 2026

• Association of preserved ratio impaired spirometry and restrictive spirometric pattern with incident atrial fibrillation: a cohort study.

  NPJ Prim Care Respir Med, Oct 2026

• Temporal Trends in Patient Characteristics, Anticoagulation Treatment Quality, and Clinical Outcomes of Individuals Receiving Vitamin K Antagonists in the Netherlands (2014 Until-2022).

  Pharmacoepidemiol Drug Saf, Oct 2026

See which targets of this disease your abstract mentions, and go to the people working on them.